Nadeem Khan, M.Sc., Ph.D.
Associate Professor of Radiology
EPR Center for Viable Systems, Department of Diagnostic Radiology
Dartmouth Medical School, Hanover, NH 03755
Investigator, Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH 03756
Ph.D. (Chemistry): 1998
M.Sc. (Chemistry): 1992
DICE (Diploma in Industrial & Computer Electronics): 1990
B.Sc. (Physics, Chemistry, Mathematics): 1989
EPR Center at Dartmouth Medical School
Norris Cotton Cancer Center
Dartmouth Medical School
HB 7785 VAIL
Hanover NH 03755
Office: 640 Rubin, Norris Cotton Cancer Center
Phone: 603 653 3591
Fax: 603 650 1717
Application of EPR oximetry to assess and repeatedly follow tumor pO2 during therapies and use this vital information to optimize therapeutic outcome
Clinical application of EPR oximetry for diagnosis and prognosis of peripheral vascular diseases
Potential application of checkpoint inhibitors to increase malignant cell death during chemoradiation
Assessment of redox status and oxygen concentration using soluble probes such as nitroxides, spin trapping of free radicals etc
RO1 CA120919 Khan (PI) 07/01/06 – 05/31/11
National Institutes of Health
Oxygen Guided Hypofractionated Radiotherapy for Gliomas
The overall goal is to demonstrate that the efficacy of the hypofractionated radiotherapy can be significantly enhanced by irradiating at times of optimal tumor oxygenation and that the use of hyperoxic therapies in conjunction with hypofractionated radiotherapy can be optimized by use of the information on oxygen levels in the tumors.
014519 Khan and Eastman (PI) 07/01/10 – 06/30/11
EISAI Inc. Andover, MA
Effect of a PARP inhibitor on tumor oxygenation and growth
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals DNA damage to repair proteins by synthesizing ADP-ribose polymers on the nuclear proteins. Consequently, inhibition of DNA repair by PARP inhibitors might enhance tumor cell death during chemotherapy and radiotherapy. The goal is to investigate the effect of a PARP inhibitor on the tissue oxygenation and growth of the gliomas when treated alone or in combination with chemotherapy.
30.058.287103 Khan and Eastman (PI) 02/01/11- 01/31/12
Norris Cotton Cancer Center, DHMC, Lebanon, NH
Oximetry-guided optimization of chemoradiation for gliomas
The overall goal is to enhance therapeutic outcome of glioma by efficaciously combining DNA damaging agents (gemcitabine and/or radiation) with SCH900776, an inhibitor of cell cycle checkpoint kinase 1 (Chk1). This will be achieved in part through an increase in the tumor pO2 (partial pressure of oxygen), which will further increase the efficacy of chemoradiation. The changes in the tumor pO2 are likely to provide an early indication of tumor response to therapy.
R21DK072112 Khan (PI) 07/01/06 - 06/30/10
National Institutes of Health
Development of EPR and NIR Oximetry for Diabetic Foot
The major goal of this project is to develop and apply two emerging techniques - Electron Paramagnetic Resonance (EPR) and Near Infrared spectroscopy (NIR) for oximetry to characterize and follow tissue oxygenation in the diabetic foot and provide data that can improve the management of the serious and widespread complication of peripheral vascular disease.
R21 CA118069 Khan (PI) 07/01/06 - 06/30/10
National Institutes of Health
Monitoring Oxygen Repeatedly for Hypoxic Tumor Therapy
The overall goal of this project is to demonstrate, under realistic conditions, that in vivo EPR oximetry can provide repetitive data on tumor oxygenation during the course of therapy and that this can be used to enhance therapeutic outcome.
P01 EB2180 Swartz(PI) 07/01/02 - 06/30/07
Measurement of pO2 in vivo and in vitro
The goal was to develop EPR oximetric material and the oximetry technique to investigate tissue pO2 in various pathologies including cancer.
POSITIONS AND EMPLOYMENT
Junior Research Fellow, North-Eastern Hill University, Shillong, India
Senior Research Fellow, North-Eastern Hill University, Shillong, India
Research Associate, University of Basel, Switzerland
Postdoctoral Fellow, Dartmouth Medical School, Hanover, NH, USA
2007 – present
Investigator, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
2002 - June, 2008
Research Assistant Professor, Dartmouth Medical School, NH, USA
July, 2009 - present
Research Associate Professor, Dartmouth Medical School, NH, USA
Member, International Society on Oxygen Transport to Tissue (ISOTT)
Member, International EPR Society (IES)
Member, Radiation Research Society (RRS)
Junior Research Fellowship, Department of Atomic Energy, New Delhi, India
Senior Research Fellowship, Department of Atomic Energy, New Delhi, India
Best Poster Award, 32nd Annual International ESR Conference, University of York, U.K.
Melvin H. Knisely Award by International Society on Oxygen Transport to Tissue (ISOTT), Rochester, New York
Young Investigator Award, International Conference/Workshop on Electron Paramagnetic Resonance Spectroscopy and Imaging of Biological Systems, September 4-8, 2005, Ohio, USA
Deep-tissue oxygen monitoring in the brain of rabbits for stroke research.
Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.
Advances in probes and methods for clinical EPR oximetry.
Real-time monitoring of ischemic and contralateral brain pO2 during stroke by variable length multisite resonators.
Clinical EPR: unique opportunities and some challenges.
Repeated assessment of orthotopic glioma pO(2) by multi-site EPR oximetry: a technique with the potential to guide therapeutic optimization by repeated measurements of oxygen.
Dynamic changes in oxygenation of intracranial tumor and contralateral brain during tumor growth and carbogen breathing: a multisite EPR oximetry with implantable resonators.
Synergistic combination of hyperoxygenation and radiotherapy by repeated assessments of tumor pO2 with EPR oximetry.
The evaluation of new and isotopically labeled isoindoline nitroxides and an azaphenalene nitroxide for EPR oximetry.
Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.